Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial

被引：0

作者：

Bajaj, Jasmohan ^{[1
]}

Yeramian, Patrick ^{[2
]}

Gavis, Edith ^{[1
]}

Fagan, Andrew ^{[1
]}

Fischer, James ^{[3
]}

Garcia-Tsao, Guadalupe ^{[4
]}

Angeli, Paolo ^{[5
]}

Smith, Denise ^{[2
]}

Adams, Jonathan ^{[2
]}

Markham, Penelope ^{[2
]}

机构：

[1] Hunter Holmes McGuire VA Ctr, Richmond, VA USA

[2] BioVie Inc, Los Angeles, CA USA

[3] Univ Illinois, Coll Pharm, Chicago, IL USA

[4] Yale Sch Med, New Haven, CT USA

[5] Univ Padua, Med, Padua, Italy

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT139

引用

页码：S718 / S719

页数：2

共 50 条

[31] Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Fleischmann, Roy
Winkle, Peter
Hall, Jesse
Yan, Xiaohong
Miner, Jeffrey N.
Hicks, Liz
Valdez, Shakti
Hernandez-Illas, Martha
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[32] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
Kudrow, David
Cady, Roger K.
Allan, Brent
Pederson, Susan M.
Hirman, Joe
Mehta, Lahar R.
Schaeffler, Barbara A.
BMC NEUROLOGY, 2021, 21 (01)
[33] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
David Kudrow
Roger K. Cady
Brent Allan
Susan M. Pederson
Joe Hirman
Lahar R. Mehta
Barbara A. Schaeffler
BMC Neurology, 21
[34] Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Chung, Vincent
Mansfield, Aaron S.
Braiteh, Fadi
Richards, Donald
Durivage, Henry
Ungerleider, Richard S.
Johnson, Francis
Kovach, John S.
CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3277 - 3284
[35] A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis
Vazquez, Jose A.
Schranz, Jennifer A.
Clark, Kay
Goldstein, Beth P.
Reboli, Annette
Fichtenbaum, Carl
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 48 (03) : 304 - 309
[36] A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer (ACC).
Li, Jian
Shen, Lin
Gong, Jifang
Peng, Zhi
Liu, Dan
Qi, Changsong
Yuan, Jiajia
Hu, Rong
Yang, Xiugao
Li, Tao
Fu, Dongxue
Yang, Ruirui
Feng, Li
Zhang, Peng
Chen, Xin
Yuan, Jing
Liu, Yuanyuan
Wu, Zhufeng
Cao, Ye
Zhong, Shulin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[37] Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
Thomas, Anish
Rajan, Arun
Berman, Arlene
Tomita, Yusuke
Brzezniak, Christina
Lee, Min-Jung
Lee, Sunmin
Ling, Alexander
Spittler, Aaron J.
Carter, Corey A.
Guha, Udayan
Wang, Yisong
Szabo, Eva
Meltzer, Paul
Steinberg, Seth M.
Trepel, Jane B.
Loehrer, Patrick J.
Giaccone, Giuseppe
LANCET ONCOLOGY, 2015, 16 (02): : 177 - 186
[38] Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study
Prins, Manon L. M.
van der Plas, Johan L.
Vissers, Maurits F. J. M.
Berends, Cecile L.
Tresch, Gaby
Soergel, Marianne
Fernandez, Elena
van den Berge, Nikita
Duijsings, Daniel
Zitt, Christof
Stavropoulou, Vaia
Zimmermann, Maya
Drake, Roxana F.
Burggraaf, Jacobus
Groeneveld, Geert H.
Kamerling, Ingrid M. C.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (03) : 1105 - 1114
[39] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
I. Kümler
P. Grundtvig Sørensen
J. Palshof
E. Høgdall
W. Skovrider-Ruminski
S. Theile
A. Fullerton
P. G. Nielsen
B. Vittrup Jensen
D. L. Nielsen
Cancer Chemotherapy and Pharmacology, 2019, 83 : 169 - 178
[40] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
Asahina, Hajime
Tamura, Yosuke
Nokihara, Hiroshi
Yamamoto, Noboru
Seki, Yoshitaka
Shibata, Takashi
Goto, Yasushi
Tanioka, Maki
Yamada, Yasuhide
Coates, Andrew
Chiu, Yi-Lin
Li, Xiaohui
Pradhan, Rajendra
Ansell, Peter J.
McKeegan, Evelyn M.
McKee, Mark D.
Carlson, Dawn M.
Tamura, Tomohide
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1477 - 1486

← 1 2 3 4 5 →